Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: a look at Alzheimer’s drug development; US-China decoupling irks Chinese biotech firms; seven potential blockbuster approvals in 2023; Novo Nordisk’s cardiovascular strategy; and a look at the vaccine and drug pipeline for monkeypox.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 23 September 2022, including: a look at Alzheimer’s drug development; US-China decoupling irks Chinese biotech firms; seven potential blockbuster approvals in 2023; Novo Nordisk A/S’s cardiovascular strategy; and a look at the vaccine and drug pipeline for monkeypox.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "The Moment Of Truth For Three Alzheimer’s Drugs Beckons: What To Expect" - Scrip, 16 Sep, 2022.)
(Also see "US-China Decoupling Gets On Biotech's Nerves" - Scrip, 20 Sep, 2022.)
(Also see "Seven Potential Blockbuster Approvals To Look Out For In 2023" - Scrip, 19 Sep, 2022.)
(Also see "Novo Nordisk Committed To Advancing In Cardiovascular" - Scrip, 20 Sep, 2022.)
(Also see "Monkeypox Vaccine, Drug Pipeline Grows Despite Signs Of Slowing Infections" - Scrip, 20 Sep, 2022.)